UBS Group
IMNP

UBS Group’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

UBS Group’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5
Closed – – 8584
2018
Q2 		$0 Sell
5
-15,643
-100% -$4.42K ﹤0.01% 8507
2018
Q1 		$5K Sell
15,648
-71,866
-82% -$34.2K ﹤0.01% 7285
2017
Q4 		$50K Buy
87,514
+80,952
+1,234% +$77K ﹤0.01% 5840
2017
Q3 		$10K Buy
6,562
+3,695
+129% +$6.46K ﹤0.01% 6921
2017
Q2 		$9K Buy
+2,867
New +$7.7K ﹤0.01% 6874
2017
Q1 		– Sell
-5,003
Closed -$18.1K – 8253
2016
Q4 		$18K Buy
5,003
+1,831
+58% +$7.52K ﹤0.01% 6600
2016
Q3 		$18K Buy
+3,172
New +$23.4K ﹤0.01% 6411
2016
Q2 		– Sell
-95
Closed -$742 – 8165
2016
Q1 		$1K Buy
95
+41
+76% +$421 ﹤0.01% 7512
2015
Q4 		$1K Sell
54
-306
-85% -$6.43K ﹤0.01% 8218
2015
Q3 		$9K Buy
360
+249
+224% +$7.84K ﹤0.01% 7369
2015
Q2 		$4K Buy
111
+81
+270% +$3.2K ﹤0.01% 8019
2015
Q1 		$1K Buy
+30
New +$1.12K ﹤0.01% 8627
2014
Q4 		– Hold
0
– – – 9708

Other funds holding IMNP

IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

UBS Group's IMNP Position: Q3 2018 in Review

UBS Group sold out of Immune Pharmaceuticals Inc. (IMNP) in Q3 2018, closing a stake of 5 shares.

UBS Group first reported a position in IMNP in Q1 2015 and held it in 12 quarters. The position peaked at $50K in Q4 2017. 1 fund tracked by Wall St. Rank holds IMNP as of Q3 2018.

  • UBS Group reported no remaining Immune Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • UBS Group sold 5 Immune Pharmaceuticals Inc. shares in Q3 2018.
  • UBS Group first reported a position in Immune Pharmaceuticals Inc. in Q1 2015 and held it in 12 quarters.
  • UBS Group's Immune Pharmaceuticals Inc. position peaked at $50K in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q3 2018.

Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.